Metrics
201,384 Downloads
Contact Share
Featured Dataverses

In order to use this feature you must have at least one published dataverse.

Publish Dataverse

Are you sure you want to publish your dataverse? Once you do so it must remain published.

Publish Dataverse

This dataverse cannot be published because the dataverse it is in has not been published.

Delete Dataverse

Are you sure you want to delete your dataverse? You cannot undelete this dataverse.

Advanced Search

There was an error with your search parameters. Please clear your search and try again.

1 to 10 of 141 Results
Who takes the lead? [Dataset]
Who takes the lead? [Dataset]
May 25, 2023 - Institut für Politische Wissenschaft - AG Tosun
Tosun, Jale; Heinz-Fischer, Christin; Luo, Rui, 2023, "Who takes the lead? [Dataset]", https://doi.org/10.11588/data/SRLY2K, heiDATA, V1, UNF:6:Yzlpf9ASvRdVtMllNS0wrg== [fileUNF]
Action is needed from all the major emitting economies if we are to achieve global net-zero carbon dioxide emissions. Climate action takes place at various levels of the political system. In this study, we concentrate on cooperation between the major economies on clean energy tec...
water_tank_labels.geojson
Apr 17, 2023 - Semi-supervised water tank detection to support vector control of emerging infectious diseases transmitted by Aedes Aegpyti [Research Data]
GeoJSON - 68.5 MB - MD5: 9ae93c1aac794d9e1a9e0f7d43080ee8
manually labelled water tank used for training and testing the water tank detection model for Rio de Janeiro
Vardarli_Suppl. Table 9.pdf
Vardarli_Suppl. Table 9.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 216.7 KB - MD5: 78f6d13d435b94fe3733e03fdaf77c63
Suppl. Table 9. Trim-and-fill results for trials investigating adrenal insufficiency any grade after immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl. Table 8.pdf
Vardarli_Suppl. Table 8.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 218.9 KB - MD5: e32fa8cb72081403d574d4d1d280e827
Suppl. Table 8. Trim-and-fill results for trials investigating hypophysitis/hypopituitarism grade 3-5 after immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl. Table 7.pdf
Vardarli_Suppl. Table 7.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 216.5 KB - MD5: c1e3211bc08d5e1fd11cb1ca68248762
Suppl. Table 7. Trim-and-fill results for trials investigating hypophysitis/hypopituitarism any grade after immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl. Table 3.xlsx
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
MS Excel Spreadsheet - 116.7 KB - MD5: 7b97c14d958dffb9cb3347b48fd10fba
Suppl. Table 3. Study characteristics of randomized controlled trials investigating endocrine adverse effects any grade and grade 3-5 after immune related checkpoint inhibitor monotherapy or combination therapy in solid tumors. NSCLC, Non-small cell lung cancer; LD-SCLC, Limited...
Vardarli_Suppl. Table 2.pdf
Vardarli_Suppl. Table 2.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 363.9 KB - MD5: 7c1640658f8d06736e3dad712a927841
Suppl. Table 2. Search strategies for randomized controlled trials investigating endocrine adverse effects any grade and grade 3-5 after immune related checkpoint inhibitor monotherapy or combination therapy in solid tumors.
Vardarli_Suppl. Table 12.pdf
Vardarli_Suppl. Table 12.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 219.2 KB - MD5: f9d8e1df71b9731cc42906df4abab368
Suppl. Table 12. Trim-and-fill results for trials investigating insulin-dependent diabetes mellitus grade 3-5 after immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl. Table 11.pdf
Vardarli_Suppl. Table 11.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 216.4 KB - MD5: 37c1389d7ef9b12de77e87300a627604
Suppl. Table 11. Trim-and-fill results for trials investigating insulin-dependent diabetes mellitus any grade after immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Vardarli_Suppl. Table 10.pdf
Vardarli_Suppl. Table 10.pdf
Nov 25, 2023 - Risk and incidence of endocrine immune related adverse effects under checkpoint inhibitor mono or combination therapy in solid tumors: a meta-analysis of randomized controlled trials [data]
Adobe PDF - 219.1 KB - MD5: b0d44cc6d4f377511600f93c84adb67c
Suppl. Table 10. Trim-and-fill results for trials investigating adrenal insufficiency grade 3-5 after immune related checkpoint inhibitor therapy in solid tumors, n= 80 trials.
Add Data

Sign up or log in to create a dataverse or add a dataset.

Sign Up Log In
Share Dataverse

Share this dataverse on your favorite social media networks.

Link Dataverse
Reset Modifications

Are you sure you want to reset the selected metadata fields? If you do this, any customizations (hidden, required, optional) you have done will no longer appear.